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Abstract
Objective—Many children diagnosed with attention-deficit/hyperactivity disorder (ADHD) 
experience co-occurring neurodevelopmental and psychiatric disorders, and those who do often 
exhibit higher levels of impairment than children with ADHD alone. This study provides a latent 
class analysis (LCA) approach to categorizing children with ADHD into comorbidity groups, 
evaluating condition expression and treatment patterns among children in each group.
Method—Parent-reported data from a large probability-based national sample of children 
diagnosed with ADHD (2014 National Survey of the Diagnosis and Treatment of ADHD and 
Tourette Syndrome) were used for an LCA to identify groups of children with similar groupings of 
neurodevelopmental and psychiatric comorbidities among children with current ADHD (n=2,495). 
Differences between classes were compared using multivariate logistic regressions.
Results—The best LCA solution placed children who were indicated to have ADHD into four 
classes: (low comorbidity (LCM) (64.5%), predominantly developmental disorders (PDD) 
(13.7%), predominantly internalizing disorders (PID) (18.5%), and high comorbidity (HCM) 
(3.3%)). Children belonging to the HCM class were most likely to have a combined ADHD 
subtype and the highest number of impaired domains. Children belonging to the PDD class were 
most likely to be receiving school services, while children in the PID class were more likely to be 
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taking medication than children belonging to the LCM class who were least likely to receive 
psychosocial treatments.
Conclusion—Latent classes based on co-occurring psychiatric conditions predicted use of varied 
treatment types. These findings contribute to the characterization of the ADHD phenotype and 
may help clinicians identify how services could best be organized and coordinated in treating 
ADHD.
Keywords
ADHD; comorbidity; national survey
INTRODUCTION
Attention-deficit/hyperactivity disorder (ADHD) is a heterogeneous neurodevelopmental 
condition that affects approximately 1 in 10 school-aged children in the United States.1 
Children diagnosed with ADHD are characterized by inattentive and/or hyperactive and 
impulsive symptoms that are developmentally inappropriate and are causing functional 
impairment across multiple settings. Children with ADHD are at a higher risk than children 
without ADHD for developing other psychiatric disorders.2,3 Previous studies, frequently 
utilizing registries and clinical or convenience samples, found more than half of children 
diagnosed with ADHD are also diagnosed with one or more co-occurring 
neurodevelopmental and psychiatric conditions, such as learning disabilities, conduct or 
externalizing problems, and internalizing or mood disorders.2, 4–7 Children with 
neurodevelopmental and psychiatric comorbidities tend to experience greater levels of 
impairment than children with ADHD alone.4, 7–8
Although the co-occurrence of neurodevelopmental and psychiatric comorbidities among 
children with ADHD has been well-documented, little research has been devoted to 
understanding the predictors that may increase a child’s likelihood of being diagnosed with a 
co-occurring neurodevelopmental or psychiatric condition. There is evidence that predictors 
for increased risk for the diagnosis of a comorbid condition include perinatal problems,9 
genetic susceptibilities,10 and receipt of an ADHD diagnosis at a young age.11 Certain co-
occurring disorders have been associated with specific ADHD subtypes, as children with the 
combined subtype are more likely to experience internalizing and externalizing disorders 
than those with either the predominantly hyperactive/impulsive or inattentive subtype.12 As 
a result, the presence of a neurodevelopmental and/or psychiatric comorbidity may have 
treatment and service use implications. In fact, children with such comorbidities may be 
more likely to respond to both therapeutic treatments and medication than children with 
ADHD only.13 Differential treatment may be dictated by the neurodevelopmental and/or 
psychiatric comorbidity itself, including cognitive-behavioral therapy for children with 
internalizing disorders,14 behavioral parent training for children with oppositional 
behaviors,15 and increased services both in and out of school for children with autism 
spectrum disorder.16
Research on the subtypes of ADHD represents part of a larger effort to better understand 
variations in the presentation of ADHD symptoms among children with ADHD. The 
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products of these efforts have included latent class analyses (LCA) designed to group 
individuals with similar symptom patterns into classes. LCAs have been shown to yield 
findings of clinical relevance, given the ability of class membership to predict serious 
cognitive and achievement deficits,17 service use patterns,7 and familial heritability18 among 
children with ADHD. These types of studies have typically relied on clinical samples or 
twin registries, with a focus on subclasses constructed from combinations of the 18 ADHD 
DSM-IV hyperactive/impulsive and inattentive symptoms.18 While informative, these 
previous studies do not provide a nationally representative population of children diagnosed 
with ADHD, as they typically are subject to sampling biases related to inclusion criteria 
required for study participation. A nationally drawn sample of a noninstitutionalized 
population of children with ADHD would avoid this source of bias, thereby helping to 
ensure that the complete spectrum of comorbid conditions present among children with 
ADHD is more fully captured.
Moreover, previous clinical studies have focused exclusively on symptoms associated with 
common co-occurring internalizing and externalizing disorders.19–21 A focus on 
symptomatology rather than diagnosed conditions could introduce additional noise into 
modeling, as capturing symptoms alone may result in not fully or accurately capturing the 
disorders one intends to measure. This may be particularly true among children with ADHD, 
given that symptoms of inattention/distractibility are also symptoms related to other 
conditions.22 Indeed, it has been recommended that an important first step towards 
expanding our knowledge of the ADHD phenotype is better understanding the presentation 
of specific co-occurring conditions among children with ADHD.23 For these reasons, the 
proposed study attempts to fill notable gaps in the literature by capturing classes of current 
parent-reported clinically diagnosed disorders (not symptoms) using a national probability-
based sample of children currently diagnosed with ADHD in the United States.
METHODS
Data Source
Data for the current study are from the 2014 National Survey of the Diagnosis and 
Treatment of Attention-Deficit/Hyperactivity Disorder and Tourette Syndrome (NS-DATA), 
a follow-up survey to the 2011–2012 National Survey of Children’s Health (NSCH), a cross-
sectional random-digit-dial telephone survey (landlines and cell phones) of US households 
with at least one child aged 0 to 17 years at the time of interview. NS-DATA, conducted by 
the National Center for Health Statistics (NCHS), was a module of the State and Local Area 
Integrated Telephone Survey and was sponsored by the National Center on Birth Defects and 
Developmental Disabilities to collect information about the diagnostic experiences of 
children 4 to 17 years old ever diagnosed with ADHD or Tourette syndrome (TS). 
Additionally, NS-DATA was designed to provide information about current and past 
medication use, behavioral interventions, and school performance. Households eligible to be 
recontacted for NS-DATA participated in the 2011–12 NSCH, had a child aged 2–15 years at 
the time of NSCH, and reported that the child had ever been diagnosed with ADHD or TS. 
The interview completion rate among households eligible to participate in NS-DATA was 
47%. NS-DATA shares the complex survey design of the NSCH, with stratification by state 
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and sample type (landline or cell phone). More information about both NS-DATA and 
NSCH, including consent procedures, can be found at http://www.cdc.gov/nchs/slaits.htm. 
Verbal consent was obtained from a parent or guardian respondent (herein referred to as the 
parent) at the time of the interview, with parents being informed of their rights as survey 
participants. The NCHS Research Ethics Review Board and the federal Office of 
Management and Budget approved all NS-DATA data collection procedures.
Sample
There were 2,966 participants included in the final interview sample for the ADHD module 
of NS-DATA, which included children who were 4–17 years old at the time of NS-DATA 
whose parent had completed the NSCH and reported at that time and confirmed in the NS-
DATA interview that they had ever been told by a doctor or other healthcare provider that 
their child had ADHD. The statistical analysis for this study was restricted to those with a 
current parent-reported ADHD diagnosis in the NS-DATA interview (n=2,495).
Measures
ADHD diagnosis—At the time of the 2014 NS-DATA survey, parents were asked to 
confirm that they had ever been told by a doctor or other healthcare provider that their child 
had ADHD as was indicated during the 2011–2012 NSCH interview. Parents were then 
asked a follow-up question after confirming a previous diagnosis, “Does [your child] 
currently have ADHD?” Children whose parents answered in the affirmative to this question 
were labeled as having a current ADHD diagnosis. Parent-reported ADHD based on a 
doctor’s diagnosis within the NSCH has been found to have high convergent validity with 
medical records.24
Co-occurring conditions—Parents were asked about whether their child had ever been 
diagnosed with 15 other conditions by a doctor or other healthcare provider, which included 
oppositional defiant disorder, conduct disorder, autism spectrum disorder or pervasive 
developmental disorder, sleep disorder, intellectual disability, learning disorder, language 
disorder, obsessive compulsive disorder, post-traumatic stress disorder, another anxiety 
disorder, bipolar disorder, intermittent explosive disorder, another mood disorder (e,g, 
depression or major depressive disorder), eating disorder, and substance use disorder. If the 
parent indicated they had ever been told that their child had a given condition, they were 
subsequently asked if the child currently had the condition.
Demographics—Child characteristics included child’s age, sex, race/ethnicity, and 
insurance type (public, private, uninsured). School characteristics included school type 
(private, public, home-school) and school population type (general, special needs). 
Household characteristics included region of residence (Northeast, Midwest, South, West), 
income recoded as federal poverty level percentage (<100%, 100% – 199%, 200% – 399%, 
≥400%), highest educational attainment of household members (less than high school, high 
school, more than high school), household type (two parent household, other), and housing 
situation (family owned, rented, other arrangement). All household variables, with the 
exception of income, were collected during the 2011–2012 NSCH.
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ADHD treatment—Parents were asked whether their child had ever taken medication for 
ADHD and if so, whether their child was currently taking medication. Parents were also 
asked if their child had received or was currently receiving any of the following treatments 
for ADHD or difficulties with their emotions, concentration or behavior: school-based 
educational support, intervention or accommodation (such as tutoring, extra help from a 
teacher, preferential seating, extra time to complete work, or being enrolled in special 
education), and classroom management (such as reward systems, behavioral modification, or 
a daily report card). Reports of current school support and classroom management were 
grouped into an indicator for current receipt of school services. Additional treatment 
questions included those asking about the ever or current receipt of peer interventions (such 
as peer tutoring or the Good Behavior Game), social skills training (such as support in how 
to interact with others), Cognitive Behavioral Therapy, or parent training; reports of current 
receipt of any of these interventions were grouped into a current psychosocial treatment 
indicator. Parents were also asked to indicate if their child had a current formal education 
plan, such as an Individualized Education Program (IEP) or 504 plan.
ADHD symptoms and overall performance outcomes—The Vanderbilt ADHD 
Parent Rating Scale (VADPRS) was adapted to be administered over the telephone to parents 
to capture ADHD symptoms and associated impairment. The VADPRS contains diagnosis-
based behavioral items intended to capture DSM-IV criteria for ADHD when the child is not 
taking medication, including 9 items measuring inattention and 9 items on hyperactivity/
impulsivity. Each item is rated on a 4 point Likert scale, and parents are instructed to “think 
about your child’s behaviors in the past 6 months when he/she is not taking medication for 
ADHD or any other medication for other difficulties with [his/her] emotions, concentration 
or behavior.” Parents could rate the frequency of a given behavior as occurring never, 
occasionally, often or very often. Behavioral items were dichotomized for analysis into 
“never”/”occasionally” and “often”/”very often”. Children who exhibited a behavior “often” 
or “very often” were coded as having the symptom. The VADPRS has been found to have 
high concurrent validity with clinical evaluations, and high reliability.25
To measure performance using a five point Likert scale from problematic to excellent, 
parents were asked to describe their child’s performance in school overall, and in reading, 
writing, and mathematics, their relationship with parents, siblings, and peers, and their 
participation in organized activities. Children whose performance was rated as “somewhat of 
a problem” or “problematic” on any of the eight performance and relationship items were 
considered to have an impaired performance.25
Parent-reported ADHD subtype—As per the VADPRS, children who had 6 or more 
inattentive symptoms, but fewer than 6 hyperactive/impulsive symptoms, and at least one 
impaired performance item, were categorized as having a predominantly inattentive ADHD 
subtype (labeled ‘inattentive only’). Children who had 6 or more hyperactive/impulsive 
symptoms, but fewer than 6 inattentive symptoms, and at least one impaired performance 
item were categorized as having a predominantly hyperactive/impulsive ADHD subtype 
(labeled ‘hyperactive/impulsive only’). Children who had 6 or more inattentive symptoms 
and 6 or more hyperactive/impulsive symptoms, and at least one impaired performance item 
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were categorized as having combined ADHD subtype (labeled ‘combined’). Children who 
met the criteria for none of these subtype groups were coded as having no ADHD subtype at 
the time of the NS-DATA (labeled as ‘neither’).
Statistical Analysis
Latent class analysis—LCA involves the formation of classes that are dictated by the 
response patterns (or profiles) of categorical indicators, with the most like individuals being 
placed together into the same classes.26 LCA can be viewed as a categorical analog to factor 
analysis, with the primary objective of reducing a series of categorical variables into a single 
categorical latent variable. However, instead of grouping like items, LCA groups like 
individuals. In this analysis, latent class models were fit using MPLUS 7.0,27 using 
maximum likelihood with robust standard errors. Missingness of covariates was modeled 
using an expectation-maximization algorithm. Ten indicators were included in the model, 
based on a current diagnosis of a co-occurring neurodevelopmental or mental health 
condition. Like conditions were grouped together, as were rare conditions, in order to 
improve the ability of the LCA to form meaningful and distinguishable classes. As such, 
intermittent explosive disorder, substance use disorder and eating disorder were grouped into 
“other disorder,” obsessive compulsive disorder, post-traumatic stress disorder, and any other 
anxiety disorder were grouped into “anxiety disorder,” and bipolar and other mood disorder 
were grouped into “mood disorder.” All other reported co-occurring disorders were 
maintained as individual indicators. Appropriate statistical methods for measuring the 
goodness of fit of class models included Akaike information criterion (AIC); Bayesian 
information criterion (BIC); and Lo-Mendell-Rubin likelihood ratio test (LMR). Entropy 
was also used as a measure of class misclassification.
Demographic differences between classes were compared utilizing corrected χ2 tests that 
accounted for the survey design (presented as F-values). Multivariate logistic regressions 
examined differences in treatment and ADHD symptomology and impairment between 
classes, adjusting for the child, school, and household characteristics listed above. 
Missingness on ADHD subtype was present for approximately 5% of cases, and missingness 
on ADHD treatments was present for approximately 4% of cases. All analyses made use of 
the survey sampling weights and the appropriate procedures to account for the complex 
survey design of the NS-DATA. Weights used in the public dataset were developed by 
NCHS which accounted for nonresponse to the questionnaire, and included a raking 
adjustment.
RESULTS
Analysis of the 10 mental health condition items among eligible participants (n=2,495) 
indicated that a 4-class model was the best fitting solution when compared to 1-, 2-, 3- and 
5-class models [See ONLINE SUPPLEMENT Table]. A Lo-Mendell-Rubin likelihood ratio 
test revealed the 4-class model had a significantly better fit than the 3-class model 
(p<0.0001), but not the 5-class model (p=0.21). The 4-class model had lower AIC, BIC, and 
BIC sample adjusted values than the 1-, 2- and 3-class models.
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Among children with current ADHD, 61.3% had at least one current co-occurring 
neurodevelopmental or psychiatric disorder. The prevalence of individual disorders among 
children with current ADHD included: oppositional defiant disorder (12.8%), conduct 
disorder (8.7%), autism spectrum disorder (13.0%), sleep disorder (12.2%), intellectual 
disability (10.8%), learning disorder (33.8%), language disorder (13.2%), any anxiety 
disorder (25.1%), any mood disorder (19.4%), and any other disorder (4.8%).
A four class solution included a class of children who, on average, had 6 co-occurring 
psychiatric conditions (3.3%) (labeled ‘high comorbidity’), a class of children averaging less 
than 1 psychiatric conditions (64.5%) (labeled ‘low comorbidity’), a class of children with 
predominantly internalizing disorders (18.5%), and a class of children with predominantly 
developmental disorders (13.7%) (Figure 1). Children that belonged to the predominantly-
developmental-disorders class were characterized by high rates of language disorder 
(62.2%), intellectual disability (47.1%), autism spectrum disorder (37.9%), and learning 
disability (85.7%). Children belonging to the predominantly-internalizing-disorders class 
were characterized by high rates of any anxiety disorder (54.4%) and any mood disorder 
(67.8%). More than four out of five children in the high comorbidity class had a current 
learning disability (96.3%), anxiety disorder (91.1%), intellectual disability (85.1%), or 
mood disorder (80.1%). Conduct disorder was commonly diagnosed in this class as well, 
with approximately three out of four children having the diagnosis (71.3%). Although less 
common, approximately two out of five children had oppositional defiant disorder (37.6%). 
Many of the children in the predominantly-internalizing-disorders class also had 
externalizing problems, with approximately one out of four children having conduct disorder 
(23.4%) and three out of ten children (29.7%) having oppositional defiant disorder. Children 
in the low comorbidity class were rarely diagnosed with another condition, with the most 
commonly diagnosed disorder—learning disability—occurring in approximately 1 in 6 
children (15.9%).
The mean number of co-occurring psychiatric disorders among children with a current 
ADHD diagnosis was 1.46 (95% CI: 1.34–1.59). Understandably, children in the high 
comorbidity class had the greatest number of co-occurring disorders (x ̄=6.76, 95% CI: 6.18–
7.35) while children in the low comorbidity group had the least (x̄=0.40, 95% CI: 0.36–
0.45). Children in the predominantly-developmental-disorders class (x̄=3.08, 95% CI: 2.89–
3.28) had a slightly higher number of co-occurring psychiatric disorders than children in the 
predominantly-internalizing-disorders class (x̄=2.67, 95% CI: 2.51–2.82). Although this 
difference was statistically significant, it was not as large as the difference found between 
children in the low and high comorbidity classes.
Demographics
Table 1 presents the child, school and household characteristics of children in each of the 
four classes. Children in the high comorbidity class were most likely to be non-Hispanic 
Black (38.4%), have current public health insurance (90.8%) or live below the federal 
poverty line (64.3%), and least likely to live with someone who has more than a high school 
education (15.2%). Children in the predominantly-developmental-disorders class (63.5%) or 
children in the low comorbidity class (66.5%) were more likely to be in a two parent 
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household than children in the predominantly-internalizing-disorders class (45.7%). 
Children in the low comorbidity class were most likely to be living in a household at or 
above 400% of the federal poverty level (28.1%) and were least likely to be in rented 
housing (32.5%). Children in the high comorbidity (26.9%), predominantly-developmental-
disorders (26.0%), and predominantly-internalizing-disorders (16.2%) classes were more 
likely to attend a special needs school than children in the low comorbidity class (5.1%).
ADHD Subtype
Figure 2 presents the prevalence of different parent-reported ADHD subtypes among 
children at the time of the survey in each of the four classes. Children in the high 
comorbidity class were the most likely to have a combined ADHD subtype (60.3%), while 
children in the low comorbidity class were the least likely to have a parent-reported ADHD 
subtype (47.8%). In total, approximately 39.6% of children with a current ADHD diagnosis 
did not have a parent-reported ADHD subtype at the time of the interview, and 
approximately 3 out of 4 of these children were placed in the low comorbidity class (73.8%) 
through the LCA. Children in the predominantly-developmental-disorders class were less 
likely to have the hyperactive/impulsive subtype (0.8%) than children in the low comorbidity 
class (3.5%) or the predominantly-internalizing-disorders class (7.3%).
ADHD Symptoms
Children in the high comorbidity class had the highest number of hyperactive/impulsive 
(x̄=6.37, 95% CI: 5.62–7.11) and inattentive (x ̄=7.14, 95% CI: 6.40–7.87) symptoms. 
Children in the predominantly-developmental-disorders class and children in the 
predominantly-internalizing-disorders class had more hyperactive/impulsive and inattentive 
symptoms than children in the low comorbidity class. Children in the predominantly-
internalizing-disorders class had more hyperactive/impulsive symptoms than children in the 
predominantly-developmental-disorders class.
Performance
On average, children experienced impairments across three domains (x̄=3.12, 95% CI: 2.95–
3.28). Children in the high comorbidity class had the highest number of domains of 
impairment (x̄=4.50, 95% CI: 3.56–5.44). Children in the predominantly-developmental-
disorders class (x̄=4.09, 95% CI: 3.61–4.58) or predominantly-internalizing-disorders class 
(x̄=3.71, 95% CI: 3.36–4.05) had a comparable number of impaired domains, which were 
both higher than children in the low comorbidity class (x̄=2.60, 95% CI: 2.41–2.79).
Treatment
Table 2 presents the current treatment usage among children in each of the four classes. 
Children in the predominantly-internalizing-disorders class (77.5%) were more likely to be 
currently taking medication for ADHD than children in the low comorbidity class (63.9%). 
Children in the predominantly-developmental-disorders class were the most likely to be 
receiving current school services (93.7%), and nine out of ten children in the predominantly-
developmental-disorders class had a formal education plan (i.e., an IEP or 504 plan). 
Children in the predominantly-developmental-disorders class (59.1%) also had higher rates 
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of current psychosocial treatment than children in the low comorbidity class (18.1%) or in 
the predominantly-internalizing-disorders class (46.2%), but had lower rates than children in 
the high comorbidity class (75.7%).
DISCUSSION
Despite a large volume of research on pediatric ADHD, there is relatively little literature on 
the role of common co-occurring disorders within the ADHD phenotype at a national 
population-based level. One way to gain insight into phenotypic variation for ADHD is 
through LCA. The current study builds upon previous population-based, birth cohort 
research28 by recruiting a large and nationally representative sample of children with a 
current parent-reported community diagnosis of ADHD. We found that approximately six 
out of ten children with current ADHD (61.3%) had a co-occurring parent-reported 
neurodevelopmental and/or mental health condition, a number similar to those found in 
other community samples and population-based surveys7,8 but lower than clinical samples 
such as the NIMH Collaborative Multisite Multimodal Treatment Study of Children with 
Attention-Deficit/Hyperactivity Disorder (MTA).29 Given clinic samples tend to recruit a 
more severe population, typically the result of stricter inclusion criteria (e.g. combined 
ADHD subtype as in the MTA), this difference is expected.30
The LCA identified four classes, which conceptually appeared to cluster by number of co-
occurring conditions (high or low comorbidity) and type of co-occurring disorder 
(predominantly-developmental-disorders or predominantly-internalizing-disorders). 
Surprisingly, despite the high co-occurrence of ADHD and disruptive behavior disorders 
(co-occurrence of oppositional-defiant disorder and conduct disorder is 44%-60%),8 a 
separate class did not emerge that represented ADHD and predominantly externalizing 
disorders. Children with these disorders were divided into the high comorbidity and 
predominantly-internalizing-disorders classes, suggesting that these children are not 
commonly diagnosed with the presence of disruptive behavior disorders without also being 
diagnosed with other disorders. It also appeared that intellectual disability and language 
disorders were highly discriminating conditions within the LCA, with both conditions 
infrequently occurring within children in the low comorbidity class and the predominantly 
internalizing disorder class.
Treatment
Children with ADHD in the predominantly-developmental-disorders class were more likely 
than other groups to receive school services, have a formal education plan, and receive 
psychosocial treatments. It is possible that the higher prevalence of intellectual disability and 
language disorders within this group may dictate the use of these services. Children with 
ADHD in the predominantly-internalizing-disorders class were more likely than children 
with low comorbidity to be taking medication for ADHD, but were less likely to be 
receiving psychosocial treatment than children in the predominantly-developmental 
disorders class and the high comorbidity class. It is possible that these children are primarily 
receiving medication to treat symptoms related to their internalizing symptoms in place of 
psychosocial treatments, an intriguing outcome given previous studies have shown 
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effectiveness in behavioral treatments yet mixed findings for stimulants in treating 
internalizing symptoms within this population.31,32
Limitations
These findings and conclusions are presented within the context of a set of limitations and 
considerations. The NS-DATA is a national survey specific to ADHD, with a large 
nationally-drawn sample of respondents about children who had been diagnosed with 
ADHD. The large sample size allowed for the comparison of multiple classes of children 
produced from an LCA, with the ability to consider multiple conditions with a low 
prevalence. Despite these strengths, this study does possess several limitations. First, the 
snapshot nature of the data prevents the ability to evaluate the developmental onset of the 
child’s co-occurring conditions, which could influence the child’s treatment.33 Future 
studies could incorporate the classes identified, but adopt a longitudinal methodology --- the 
use of latent-class growth analysis may provide additional insight into the evolving needs of 
children with varying clinical presentations. Second, the parent-reported information about 
treatment and mental health diagnoses was not validated by a clinician. As a result, it is not 
possible to rule out unmeasured confounding among children who may have an undiagnosed 
condition or received an inappropriate diagnosis. Moreover, although parents were asked to 
consider their child’s condition while not using medications when answering questions 
about their child’s current ADHD symptoms, it is not known if parents likewise considered 
their child’s condition while not receiving non-pharmaceutical treatments. In some instances 
parents reported their child to have a sub-threshold number of symptoms in the past 6 
months for a clinical diagnosis; this may indicate that the parent did not consider the child 
when off medication, or could suggest that the child no longer had the condition. 
Additionally, the VADPRS does not require impairment across two settings, which is a 
requirement in making an ADHD diagnosis. Nonetheless, there is evidence that parent report 
of a neurodevelopmental or psychiatric disorder diagnosis has good convergent validity with 
other epidemiological methods of characterizing these disorders24 and the majority of 
children in the sample were diagnosed following best practices.34 Moreover, the 
demographic composition of the population of children ever diagnosed with ADHD based 
on NS-DATA was comparable to children ever diagnosed with the disorder based on the 
2011–2012 NSCH as well as the 2011 and 2012 National Health Interview Survey.
Finally, due to the implementation of the NS-DATA survey taking place approximately 2 
years (median=29 months) after the initial report of an ADHD diagnosis in the 2011–12 
NSCH, only children who had an ADHD diagnosis for two or more years are represented in 
the NS-DATA sample, and these children may display a different phenotype regarding 
current co-occurring conditions than children with a more recent diagnosis.
Estimates based on telephone surveys with low response rates may be biased due to 
differences between respondents and nonrespondents. The final response rate for NS-DATA 
was 11%, but this is a misleading estimate of the potential for nonresponse bias in weighted 
estimates. Because NS-DATA was a follow-back survey to the NSCH, the NS-DATA 
response rate is the NS-DATA interview completion rate (47%) multiplied by the NSCH 
final response rate (23%). The NSCH sample weights were adjusted to account for known 
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demographic correlates of nonresponse and were calculated in accordance with best 
practices for sample surveys, and the NS-DATA sample weights were adjusted to account for 
follow-back nonresponse (using NSCH data for respondents and nonrespondents alike to 
precisely identify correlates of response propensity), but bias resulting from nonresponse 
cannot be completely ruled out. However, it should be noted that a nonresponse bias analysis 
was conducted to examine estimates before and after the nonresponse weighting 
adjustments, and results indicated that bias was found to greatly decrease after the weighting 
adjustments, and the estimated observable biases using the final weights tended to be smaller 
than sampling error (i.e., not statistically significant).35 Finally, the 47% interview 
completion rate of the NS-DATA should not be interpreted as a 53% refusal rate because it 
includes households that could not be recontacted. Among recontacted households, the 
interview completion rate for NS-DATA (i.e., the cooperation rate) exceeded 80%.
Implications
Just as diagnostic classifications help clinicians identify the most promising treatments, the 
classes identified in the current study may help clinicians identify how services could best be 
organized and coordinated, in accordance with AAP guidelines for diagnosing, evaluating 
and treating ADHD.36 For example, children in the high comorbidity class are the most 
likely to have complex treatment needs. In such instances, the AAP guidelines recommend 
family-centered coordinated care in a medical home, a standard for high-quality 
comprehensive health care that is often lacking for children with ADHD.37 Children in the 
predominantly-developmental-disorders class are nearly certain to need or receive school 
services. Previous research by Cooley and colleagues38 has shown that a collaboration 
between school and medical professionals yields good outcomes, including appropriate 
referrals. Children in the predominantly-internalizing-disorders class may be more likely 
than others to need medication. In circumstances where the child has severe mood or anxiety 
disorders, which could alter the treatment of ADHD, AAP guidelines recommend primary 
care clinicians seek support and guidance from subspecialists for assessment and 
management. Pediatric primary clinician-child psychiatric collaborations39 have been shown 
to decrease unmet psychiatric needs among this population of children.40 Taken together, 
these findings contribute to the characterization of the ADHD phenotype and relate 4 classes 
of clinical presentation to functional outcomes and treatment usage.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Prevalence of mental health conditions in children with current ADHD, by class
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Figure 2. ADHD subtype among children with current ADHD, by class
Notes: a significantly differs from predominantly-developmental-disorders class (p<.05);
b
 significantly differs from predominantly-internalizing-disorders class (p<.05);
c
 significantly differs from high comorbidity class (p<.05)
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